文献速递生殖医学

母体循环肾素原与卵母细胞及植入前胚胎发育:鹿特丹围受孕期队列研究

Circulating maternal prorenin and oocyte and preimplantation embryo development: the Rotterdam Periconception Cohort.
PubMed 文献 · Hum Reprod · 2023-01-01

该前瞻性观察队列研究纳入2017年5月至2020年7月接受体外受精或卵胞浆内单精子注射的309对夫妇,对1024枚胚胎进行延时培养。调整患者和治疗相关因素后,较高母体循环肾素原浓度与卵母细胞面积更大、五细胞期后卵裂更快、受精卵母细胞数更多及植入几率增加相关,但与活产无关。

要点

  • 卵巢刺激后较高的母体循环肾素原浓度与卵母细胞面积增大相关。
  • 较高肾素原与五细胞期后卵裂速度加快及受精卵母细胞数增多相关。
  • 较高肾素原与植入几率增加相关,但与活产无显著关联。

核心结论

  • 卵巢刺激后较高的母体循环肾素原浓度与卵母细胞面积更大、五细胞期后卵裂更快以及植入成功几率增加相关。

研究设计与样本

  • 前瞻性观察队列研究,作为正在进行的鹿特丹围受孕期队列研究的亚队列,于2017年5月起在一家三级转诊医院开展。
  • 2017年5月至2020年7月纳入309对具有体外受精或卵胞浆内单精子注射指征的夫妇,共1024枚胚胎进行延时胚胎培养。
  • 回顾性记录受精时间、原核出现和消失时间以及达到二至八细胞期、囊胚开始形成、达到完整囊胚和扩张囊胚的精确时间。
  • 在受精时间、原核出现和原核消失时测量卵母细胞面积;在胚胎移植日测定肾素原。

主要发现

  • 调整患者和治疗相关因素后,线性混合模型显示较高肾素原浓度与tPNa时卵母细胞面积更大相关(β 64.45 µm2,95% CI 3.26; 125.64,P = 0.04)。
  • 较高肾素原浓度与五细胞期起进展更快相关(例如八细胞期β -1.37 h,95% CI -2.48; -0.26,P = 0.02)。
  • 肾素原与移植前结局呈正相关(例如受精卵母细胞数β 2.09,95% CI 1.43; 2.75,P < 0.001)。
  • 肾素原与植入相关(β-hCG检测比值比 1.79,95% CI 1.06; 3.08,P = 0.03),但与活产无关。

局限性

  • 这项前瞻性观察研究提供的是关联性结果,因此不能排除残余混杂,因果关系需在干预研究中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Could circulating maternal prorenin serve as a proxy for oocyte and preimplantation embryo development, assessed by time-lapse parameters and clinical treatment outcomes? SUMMARY ANSWER: High circulating maternal prorenin concentrations after ovarian stimulation associate with a larger oocyte area, faster cleavage divisions from the five-cell stage onwards and increased chance of successful implantation. WHAT IS KNOWN ALREADY: After ovarian stimulation, circulating prorenin (renin's precursor), is largely ovary-derived. Prorenin may contribute to ovarian angiotensin synthesis, which is relevant in reproduction given its role in follicular development and oocyte maturation. STUDY DESIGN, SIZE, DURATION: Prospective observational cohort study including couples requiring fertility treatment from May 2017 as a subcohort of the ongoing Rotterdam Periconception Cohort conducted in a tertiary referral hospital. PARTICIPANTS/MATERIALS, SETTING, METHODS: Between May 2017 and July 2020, 309 couples with an indication for IVF treatment or ICSI were included. Resulting embryos (n = 1024) were submitted to time-lapse embryo culture. Time of fertilization (t0), pronuclear appearance (tPNa), and fading (tPNf) as well as the exact timing of reaching the two- to eight-cell stage (t2-t8), the start of blastulation (tSB), reaching the full (tB), and expanded blastocyst (tEB) were retrospectively recorded. Oocyte area was measured at t0, tPNa, and tPNf. Prorenin was determined at the day of embryo transfer. MAIN RESULTS AND THE ROLE OF CHANCE: After adjustment for patient- and treatment-related factors, linear mixed modeling showed that higher prorenin concentrations associate with a larger oocyte area at tPNa (β 64.45 µm2, 95% CI 3.26; 125.64, P = 0.04), and faster progression from five-cell stage onwards (e.g. β8-cell -1.37 h, 95% CI -2.48; -0.26, P = 0.02). Prorenin associated positively with pre-transfer outcomes (e.g. βfertilized oocytes 2.09, 95% CI 1.43; 2.75, P < 0.001) and implantation (odds ratio+β-hCG-test: 1.79, 95% CI 1.06; 3.08, P = 0.03), but not with live birth. LIMITATIONS, REASONS FOR CAUTION: This prospective observational study provides associations and therefore residual confounding cannot be excluded and causality has to be shown in intervention studies. WIDER IMPLICATIONS OF THE FINDINGS: Theca cell-derived factors, such as prorenin, may help to clarify the underlying endocrine mechanism of oocyte maturation and embryo development, with a special focus on the (patho)physiological reproductive role of prorenin and the identification of factors influencing its secretion and activity, which is of great added value for improving embryo selection and predicting implantation and pregnancy outcomes. This will bring us to investigate which determinants of oocyte quality and embryo development should take center stage in developing preconception care strategies. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by the Department of Obstetrics and Gynecology of the Erasmus MC, University Medical Center, Rotterdam, the Netherlands, and the Erasmus MC Medical Research Advisor Committee's 'Health Care Efficiency Research' program (OZBS72.16080). The authors have no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Wiegel RE, Danser AHJ, van Duijn L, et al. Circulating maternal prorenin and oocyte and preimplantation embryo development: the Rotterdam Periconception Cohort. Hum Reprod. 2023. PMID: 36795035. doi:10.1093/humrep/dead030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。